Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Spevatamig · PT-886

Bispecific antibody · Immune activation, directed at Claudin-18.2 (CLDN18) and CD47

Phase 1/2 Most advanced trial
1 Registered trials

What is Spevatamig?

Spevatamig is a bispecific antibody targeting Claudin-18.2 and CD47. It binds CLDN18.2 on tumor cells and blocks CD47-SIRPα interactions, promoting macrophage phagocytosis and T-cell-mediated killing. It is studied in gastric, pancreatic, biliary, and colorectal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PT-886
Drug type
Bispecific antibody
Targets
Claudin-18.2 (CLDN18), CD47, Signal regulatory protein alpha (SIRPA) (binding partner it blocks)
Mechanism
Immune activation, directed at Claudin-18.2 (CLDN18) and CD47
Pathways
phagocytosis, T-cell-mediated killing, ADCC, ADCP
Therapy area
Oncology
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
LVB74L4PM2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05482893 Phase 1/2 Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Biliary Tract Cancer (BTC)Colorectal CancerGastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal Adenocarcinoma

Other drugs acting on CLDN18 / CD47

Evorpacept Phase 2/3 Ligufalimab Phase 3 Osemitamab Phase 1/2 Sonesitatug Vedotin Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.